Y Intercept Hong Kong Ltd Makes New $558,000 Investment in Mesa Laboratories, Inc. $MLAB

Y Intercept Hong Kong Ltd purchased a new position in Mesa Laboratories, Inc. (NASDAQ:MLAB) during the first quarter, HoldingsChannel.com reports. The fund purchased 6,315 shares of the medical instruments supplier’s stock, valued at approximately $558,000.

Several other hedge funds and other institutional investors have also modified their holdings of MLAB. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Mesa Laboratories by 4.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier’s stock valued at $364,000 after buying an additional 143 shares during the last quarter. American Century Companies Inc. boosted its stake in Mesa Laboratories by 1.5% in the second quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier’s stock valued at $1,265,000 after acquiring an additional 194 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of Mesa Laboratories by 30.9% during the third quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock valued at $69,000 after purchasing an additional 243 shares during the last quarter. Deutsche Bank AG raised its position in shares of Mesa Laboratories by 5.9% during the 4th quarter. Deutsche Bank AG now owns 4,440 shares of the medical instruments supplier’s stock worth $349,000 after purchasing an additional 248 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its position in shares of Mesa Laboratories by 5,366.7% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 322 shares during the period. 90.60% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Mesa Laboratories

In other news, CFO John Sakys sold 2,827 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total transaction of $253,016.50. Following the transaction, the chief financial officer directly owned 19,785 shares of the company’s stock, valued at approximately $1,770,757.50. This trade represents a 12.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Lyndsey Elizabeth Crennen sold 442 shares of Mesa Laboratories stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $39,559.00. Following the sale, the chief accounting officer owned 2,020 shares in the company, valued at approximately $180,790. This represents a 17.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 8,277 shares of company stock valued at $770,122. 4.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $94.00.

Mesa Laboratories Stock Performance

MLAB opened at $94.95 on Tuesday. The business’s 50 day moving average is $101.69 and its 200-day moving average is $93.05. The stock has a market cap of $524.12 million, a PE ratio of 79.12 and a beta of 0.93. The company has a current ratio of 1.72, a quick ratio of 1.29 and a debt-to-equity ratio of 0.78. Mesa Laboratories, Inc. has a twelve month low of $55.45 and a twelve month high of $113.99.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings data on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.78 by ($0.25). Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.The business had revenue of $63.72 million during the quarter, compared to the consensus estimate of $65.21 million. During the same period last year, the company earned ($1.31) earnings per share.

Mesa Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Monday, August 31st. Mesa Laboratories’s payout ratio is 53.33%.

Mesa Laboratories Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.